Stem Cell Therapy - From Step to Step

We are searching data for your request:

Forums and discussions:

Manuals and reference books:

Data from registers:

Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.

Both in childhood and adulthood, non-cancerous malignant blood cancers and lymphoid diseases can occur, with the only known cure for stem cell transplantation today.

International data processing has shown that the transplantation of stem cells of other human origin (allogeneic transplantation) or of its own (autologous transplantation) is associated with a number of malignant diseases, severe cancer, and cancer. It may be the first choice of treatment for certain illnesses, but the decision must always be preceded by careful consideration of the condition of the patient, the stage of the disease and the risks of intervention. For allogeneic transplantation, proper donor selection, donor and recipient serological, functional, and molecular HLA reconciliation, medical necessity for the recipient, and the donor are assured.

How do I get accepted?

The patient must be able to be admitted before the implantation of the stem cell. In the case of a suitable donor and recipient, the patient will undergo special treatment (conditioning). The aim of the treatment is to destroy the patient's own blood-forming system and immune system, which makes it suitable for receiving donor cells.
Conditioning treatment varies depending on the underlying disease. In non-malignant diseases, the goal is immunological preparation, i.e., adherence of the donor cell. In malignant diseases, conventional transplantation (conditioning) high-dose chemotherapy that facilitates transplantation may be associated with total body irradiation (TBI) or radiation without radiation. Radiotherapy can also be replaced by high-dose chemotherapy agents. This treatment was based on the hypothesis that bone marrow cell killing (myeloablative) chemotherapy and TBI not only destroy the host's haematopoietic immune system, but also completely eradicate it. However, it has been known that intensive conditioning can lead to damage to the stomach, liver, lungs and heart. As it is considered traditional, high-dose conditioning treatment is therefore recommended only for the treatment of younger patients (<50-55 years), whose vital organs are in good medical condition. Unfortunately, this limitation excludes many patients from the possibility of transplantation treatment.

Transplantation Treatments That Have Not Completely Destroyed Bone Marrow Imaging

Over the last 6-7 years, clinical trials have focused on non-myeloblastic transplantation treatments that have not completely eradicated bone marrow. The strategy is based on the use of less toxic agents and does not completely eliminate bone marrow imaging. However, this conditioning treatment does not overcome the severe weakening of the immune system as it ensures adherence of the donor cells administered. This is called immunosuppression. In addition to adherence to donor cells, another goal is to kill the underlying disease, which in this case has been repeatedly given, and can be achieved by infections of the same donor from T-lymphocytes. With a less toxic treatment, transplantation can be achieved for those in whom conventional high-dose treatment would cause life-threatening events.